PRINCETON, N.J., June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO - News) announced today that the U.S. International Trade Commission (ITC) has launched an investigation of Sanofi-Aventis's importation of the OptiClik® pen system. Novo Nordisk filed a complaint with the ITC last month alleging that OptiClik and the medication cartridges sold for use with the system infringe a Novo Nordisk U.S. patent and unfairly harm Novo Nordisk's efforts to produce insulin delivery devices in the U.S.
